Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice.

ABSTRACT: Myeloperoxidase (MPO) activity has been associated with the metabolic syndrome, cardiovascular and liver disease. Here, we evaluate the therapeutic potential of MPO inhibition on nonalcoholic steatohepatitis (NASH) and NASH-induced fibrosis, the main determinant of outcomes. MPO plasma levels were elevated in patients with nonalcoholic fatty liver disease (NAFLD) compared with healthy controls. In a second cohort, hepatic MPO messenger RNA expression correlated with higher body mass index and hemoglobin A1c, both being risk factors for NAFLD. We could establish by immunohistochemistry that MPO-positive cells were recruited to the liver in various mouse models of fibrogenic liver injury, including bile duct ligation, carbon tetrachloride (CCl₄) treatment, spontaneous liver

SUBMITTER: Koop AC 

PROVIDER: S-EPMC7527691 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature